Specific heat of UPdâ Siâ

The specific heat of single-crystal U Pd2 Si2 has been studied using both the step heating and continious heating methods for the temperature range 2 to 250 K. Successive phase transitions at Tl = 136I< and T2 = 108I< are reported, which are consistent with current publications. The transition at 40K, which was previously reported, has not been detected. Recent published elastic neutron scattering data, magnetic susceptibility and resistivity results suggest that U Pd2 Si2 may be a heavy fermion compound, however, the electronic specific heat coefficient I (= 18.97 ;~), obtained from the specific heat Cv measurements, is smaller than that of the conventional heavy fermion system. The Debye temperature of U Pd2Si2 is found to be 116.55K. The possibility is discussed that the maximum in CIT in the low-temperature range 2 to 4K corresponds to Schottky anomaly induced by localized magnetic impurities .

Chronic versus acute ingestion of sodium citrate: a randomized placebo controlled cross-over trial for swimming 200 metres in well-trained swimmers age 13-17

A double-blinded, placebo controlled, cross-over design was used to investigate sodium citrate dihydrate (Na-CIT) supplementation improve 200m swimming performance. Ten well-trained, male swimmers (14.9 ± 0.4y; 63.5 ± 4kg) performed four 200m time trials: acute (ACU) supplementation (0.5g/kg), acute placebo (PLC-A), chronic (CHR) (0.1g/kg for 3 days and 0.3g/kg on the 4th day pre-trial), and chronic placebo (PLC-C). Na-CIT was administered 120min pre-trial in solution with 500mL of flavored water; placebo was flavored water. Blood lactate, base excess (BE), bicarbonate, pH, and PCO2 were analyzed at basal, 100min post-ingestion, and 3min post-trial via finger prick. Time, lactate, and rate of perceived exertion were not different between trials. BE and bicarbonate were significantly higher for the ACU and CHR trials compared to placebo. “Responders” improved by 1.03% (P=0.043) and attained significantly higher post-trial lactate concentrations in the ACU versus PLC-A trials and compared to non-responders in the ACU and CHR trials.